CRESCENT BIOPHARMA, INC. 8-K

What Happened
Crescent Biopharma, Inc. announced its quarterly financial results for the quarter ended March 31, 2026, in a press release issued on April 29, 2026. The company filed a Current Report on Form 8‑K (Item 2.02) to furnish that press release (Exhibit 99.1). The filing was signed by CEO Joshua Brumm.

Key Details

• Filing date: April 29, 2026 (Form 8‑K, Item 2.02).
• Quarter covered: Quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form signed by Joshua Brumm, Chief Executive Officer.

Why It Matters
This 8‑K notifies investors that Crescent Biopharma has publicly released its quarterly results; those results (revenue, earnings/loss, cash position, and management commentary) are contained in the press release. Quarterly results are a key update for retail investors because they can affect the company’s stock performance and provide insight into operational and financial trends. Investors should read the attached press release (Exhibit 99.1) for the detailed financial figures and any forward-looking statements or guidance.